When a skin graft or surgical flap begins to fail, surgeons have a narrow window to intervene before tissue necrosis becomes irreversible. Hyperbaric oxygen therapy (HBOT) has emerged as a critical salvage therapy in these scenarios — and new 2026 research adds quantitative support to its efficacy.
The Vascular Challenge in Reconstructive Surgery
Skin grafts and flaps represent the workhorse of reconstructive surgery, from burn reconstruction to post-oncologic repair. Yet these transplanted tissues remain vulnerable until neovascularization establishes a robust blood supply. When venous congestion, arterial insufficiency, or hematoma formation compromise perfusion, graft failure rates can exceed 30% without intervention.
The physiological stakes are immediate. Without adequate oxygen delivery, fibroblasts cease collagen synthesis within hours. Endothelial cells lining capillary buds undergo apoptosis. The cascade accelerates rapidly: edema compounds vascular compromise, thrombosis propagates, and tissue loss becomes inevitable.
How HBOT Interrupts the Ischemic Cascade
Hyperbaric oxygen therapy delivers 100% oxygen at pressures typically between 2.0 and 2.5 atmospheres absolute (ATA). Under these conditions, the physical laws of gas dissolution shift dramatically. Plasma oxygen concentration increases from roughly 0.3 mL/dL to over 6 mL/dL — sufficient to meet resting tissue metabolic requirements without hemoglobin-bound oxygen.
This hyperoxygenation achieves several therapeutic objectives simultaneously. Oxygen diffusion gradients extend deeper into ischemic tissue zones, maintaining cellular viability at the graft-host interface. Neutrophil oxidative killing capacity restores, reducing infection risk in the vulnerable early postoperative period. Perhaps most critically, HBOT triggers upregulation of vascular endothelial growth factor (VEGF) and other angiogenic cytokines, accelerating capillary ingrowth from recipient bed to graft.
2026 Evidence: Quantified Benefits
A narrative review published in Frontiers in Surgery this year synthesized current evidence for optimizing skin graft outcomes, with particular attention to adjunctive therapies. The analysis highlighted a randomized controlled trial demonstrating that postoperative HBOT significantly improved early graft survival in patients undergoing medium-thickness skin grafting for post-traumatic wounds.
The mechanism aligns with established physiological principles. By maintaining tissue oxygen tension above critical thresholds during the vulnerable first 72 hours, HBOT bridges the gap between graft placement and functional revascularization. The therapy effectively extends the ischemic tolerance of transplanted tissue, buying time for natural angiogenesis to establish sustainable perfusion.
FDA Recognition and Clinical Criteria
The FDA includes compromised skin grafts and flaps among its cleared indications for hyperbaric oxygen therapy. This designation reflects decades of clinical experience and supportive literature, though the evidence base consists primarily of case series and physiological studies rather than large randomized trials — a common pattern for time-critical surgical interventions where placebo-controlled designs face ethical and practical obstacles.
Clinical protocols typically involve twice-daily treatments at 2.0-2.4 ATA for 90 minutes each, continuing until graft viability stabilizes — usually 5 to 10 sessions. Treatment initiation within 24 hours of vascular compromise appears to optimize outcomes, though delayed intervention can still salvage partially threatened tissue.
Patient selection requires careful assessment. HBOT benefits grafts with marginal perfusion or venous congestion, but cannot rescue tissue that has already undergone irreversible ischemic necrosis. Surgeons evaluate capillary refill, dermal bleeding, and tissue turgor to identify salvageable grafts versus those requiring debridement and revision.
Beyond the Operating Room: Broader Applications
The principles underlying HBOT for graft salvage extend to related indications. Delayed radiation injury, another FDA-cleared use, similarly involves compromised vascularity in previously irradiated tissue beds. Chronic refractory osteomyelitis and thermal burns share the common denominator of tissue hypoxia that HBOT addresses through hyperoxygenation and angiogenic stimulation.
This physiological coherence explains why major academic medical centers — including Duke, Mayo Clinic, and Cleveland Clinic — maintain hyperbaric medicine services as integral components of their wound care and reconstructive surgery programs. The therapy occupies a specific niche: not first-line for uncomplicated grafts, but potentially graft-saving when vascular compromise threatens failure.
Safety Considerations and Limitations
HBOT requires administration in specialized facilities with trained personnel. Barotrauma to ears or sinuses affects a minority of patients, usually manageable with technique modification. Oxygen toxicity seizures occur rarely, typically without lasting sequelae when pressure is reduced promptly. The 2025 FDA safety communication emphasized proper chamber maintenance and fire prevention protocols, particularly relevant given the oxygen-enriched environment.
Contraindications include untreated pneumothorax and certain chemotherapeutic agents. Relative contraindications — claustrophobia, uncontrolled fever, active upper respiratory infection — require individualized risk-benefit assessment.
The Bottom Line
For compromised skin grafts and flaps, hyperbaric oxygen therapy offers a physiologically grounded salvage option with FDA-cleared status and supportive clinical evidence. The 2026 Frontiers review reinforces its role in the reconstructive surgeon’s armamentarium, particularly when early graft perfusion falls below critical thresholds. As with all HBOT applications, appropriate patient selection and timely intervention distinguish successful outcomes from missed opportunities.
The therapy exemplifies a broader principle in hyperbaric medicine: oxygen, delivered under pressure, can sustain tissue viability when conventional perfusion fails — extending surgical possibilities and improving functional outcomes for patients facing reconstructive challenges.